Gary W. Miller

Prof. Gary W. Miller

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Science
Verified
Journal Article
Closed access
PDF file
RVRoel Vermeulen
Roel Vermeulen
ESEmma Schymanski
Emma Schymanski
ABAlbert-László Barabási
Albert-László Barabási
GMGary W. Miller
Gary W. Miller
Despite extensive evidence showing that exposure to specific chemicals can lead to disease, current research approaches and regulatory policies fail to address the chemical complexity of our world. To safeguard current and future generations from the increasing number of chemicals polluting our environment, a systematic and agnostic approach is needed. The “exposome” concept strives to capture the diversity and range of exposures to synthetic chemicals, dietary constituents, psychosocial stressors, and physical factors, as well as their corresponding biological responses. Technological advances such as high-resolution mass spectrometry and network science have allowed us to take the first steps toward a comprehensive assessment of the exposome. Given the increased recognition of the dominant role that nongenetic factors play in disease, an effort to characterize the exposome at a scale comparable to that of the human genome is warranted.

9 November 2013 in Toxicological Sciences
Verified
Journal Article
Closed access
GMGary W. Miller
Gary W. Miller
DJDean P. Jones
Dean P. Jones

25 November 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PSPradnya P. Samant
Pradnya P. Samant
MNMegan M. Niedzwiecki
Megan M. Niedzwiecki
NRNicholas Raviele
Nicholas Raviele
VTVilinh Tran
Vilinh Tran
JMJuan Mena-Lapaix
Juan Mena-Lapaix
MPMark R. Prausnitz
Mark R. Prausnitz
Interstitial fluid from skin sampled with a microneedle-based method identified clinically relevant metabolic biomarkers in humans compared to plasma.

25 July 2007 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
WCW. Michael Caudle
W. Michael Caudle
Jason RichardsonJason Richardson
Jason Richardson
MWMin Z. Wang
Min Z. Wang
TTTonya N. Taylor
Tonya N. Taylor
TGThomas S. Guillot
Thomas S. Guillot
GMGary W. Miller
Gary W. Miller
The vesicular monoamine transporter 2 (VMAT2; SLC18A2) is responsible for packaging dopamine into vesicles for subsequent release and has been suggested to serve a neuroprotective role in the dopamine system. Here, we show that mice that express ∼5% of normal VMAT2 (VMAT2 LO) display age-associated nigrostriatal dopamine dysfunction that ultimately results in neurodegeneration. Elevated cysteinyl adducts tol-DOPA and DOPAC are seen early and are followed by increased striatal protein carbonyl and 3-nitrotyrosine formation. These changes were associated with decreased striatal dopamine and decreased expression of the dopamine transporter and tyrosine hydroxylase. Furthermore, we observed an increase in α-synuclein immunoreactivity and accumulation and neurodegeneration in the substantia nigra pars compacta in aged VMAT2 LO mice. Thus, VMAT2 LO animals display nigrostriatal degeneration that begins in the terminal fields and progresses to eventual loss of the cell bodies, α-synuclein accumulation, and anl-DOPA responsive behavioral deficit, replicating many of the key aspects of Parkinson's disease. These data suggest that mishandling of dopamine via reduced VMAT2 expression is, in and of itself, sufficient to cause dopamine-mediated toxicity and neurodegeneration in the nigrostriatal dopamine system. In addition, the altered dopamine homeostasis resulting from reduced VMAT2 function may be conducive to pathogenic mechanisms induced by genetic or environmental factors thought to be involved in Parkinson's disease.

24 June 2009 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
TTTonya N. Taylor
Tonya N. Taylor
WCW. Michael Caudle
W. Michael Caudle
KSKennie R. Shepherd
Kennie R. Shepherd
ANAliReza Noorian
AliReza Noorian
CJChad R. Jackson
Chad R. Jackson
GMGary W. Miller
Gary W. Miller
Parkinson9s disease (PD) is a progressive neurodegenerative disorder that is characterized by the loss of dopamine neurons in the substantia nigra pars compacta, culminating in severe motor symptoms, including resting tremor, rigidity, bradykinesia, and postural instability. In addition to motor deficits, there are a variety of nonmotor symptoms associated with PD. These symptoms generally precede the onset of motor symptoms, sometimes by years, and include anosmia, problems with gastrointestinal motility, sleep disturbances, sympathetic denervation, anxiety, and depression. Previously, we have shown that mice with a 95% genetic reduction in vesicular monoamine transporter expression (VMAT2-deficient, VMAT2 LO) display progressive loss of striatal dopamine, l-DOPA-responsive motor deficits, α-synuclein accumulation, and nigral dopaminergic cell loss. We hypothesized that since these animals exhibit deficits in other monoamine systems (norepinephrine and serotonin), which are known to regulate some of these behaviors, the VMAT2-deficient mice may display some of the nonmotor symptoms associated with PD. Here we report that the VMAT2-deficient mice demonstrate progressive deficits in olfactory discrimination, delayed gastric emptying, altered sleep latency, anxiety-like behavior, and age-dependent depressive behavior. These results suggest that the VMAT2-deficient mice may be a useful model of the nonmotor symptoms of PD. Furthermore, monoamine dysfunction may contribute to many of the nonmotor symptoms of PD, and interventions aimed at restoring monoamine function may be beneficial in treating the disease.

9 September 2015 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
YGYoung-Mi Go
Young-Mi Go
DWDouglas I. Walker
Douglas I. Walker
YLYongliang Liang
Yongliang Liang
Karan UppalKaran Uppal
Karan Uppal
QSQuinlyn A. Soltow
Quinlyn A. Soltow
DJDean P. Jones
Dean P. Jones
The exposome is the cumulative measure of environmental influences and associated biological responses throughout the lifespan, including exposures from the environment, diet, behavior, and endogenous processes. A major challenge for exposome research lies in the development of robust and affordable analytic procedures to measure the broad range of exposures and associated biologic impacts occurring over a lifetime. Biomonitoring is an established approach to evaluate internal body burden of environmental exposures, but use of biomonitoring for exposome research is often limited by the high costs associated with quantification of individual chemicals. High-resolution metabolomics (HRM) uses ultra-high resolution mass spectrometry with minimal sample preparation to support high-throughput relative quantification of thousands of environmental, dietary, and microbial chemicals. HRM also measures metabolites in most endogenous metabolic pathways, thereby providing simultaneous measurement of biologic responses to environmental exposures. The present research examined quantification strategies to enhance the usefulness of HRM data for cumulative exposome research. The results provide a simple reference standardization protocol in which individual chemical concentrations in unknown samples are estimated by comparison to a concurrently analyzed, pooled reference sample with known chemical concentrations. The approach was tested using blinded analyses of amino acids in human samples and was found to be comparable to independent laboratory results based on surrogate standardization or internal standardization. Quantification was reproducible over a 13-month period and extrapolated to thousands of chemicals. The results show that reference standardization protocol provides an effective strategy that will enhance data collection for cumulative exposome research. In principle, the approach can be extended to other types of mass spectrometry and other analytical methods.